Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Requirement of FAT and DCHS protocadherins during hypothalamic-pituitary development
Emily J. Lodge, Paraskevi Xekouki, Tatiane S. Silva, Cristiane Kochi, Carlos A. Longui, Fabio R. Faucz, Alice Santambrogio, James L. Mills, Nathan Pankratz, John Lane, Dominika Sosnowska, Tina Hodgson, Amanda L. Patist, Philippa Francis-West, Françoise Helmbacher, Constantine A. Stratakis, Cynthia L. Andoniadou
Emily J. Lodge, Paraskevi Xekouki, Tatiane S. Silva, Cristiane Kochi, Carlos A. Longui, Fabio R. Faucz, Alice Santambrogio, James L. Mills, Nathan Pankratz, John Lane, Dominika Sosnowska, Tina Hodgson, Amanda L. Patist, Philippa Francis-West, Françoise Helmbacher, Constantine A. Stratakis, Cynthia L. Andoniadou
View: Text | PDF
Research Article Development Endocrinology

Requirement of FAT and DCHS protocadherins during hypothalamic-pituitary development

  • Text
  • PDF
Abstract

Pituitary developmental defects lead to partial or complete hormone deficiency and significant health problems. The majority of cases are sporadic and of unknown cause. We screened 28 patients with pituitary stalk interruption syndrome for mutations in the FAT/DCHS family of protocadherins that have high functional redundancy. We identified 7 variants, 4 of which are putatively damaging, in FAT2 and DCHS2 in 6 patients with pituitary developmental defects recruited through a cohort of patients with mostly ectopic posterior pituitary gland and/or pituitary stalk interruption. All patients had growth hormone deficiency, and 2 presented with multiple hormone deficiencies and small glands. FAT2 and DCHS2 were strongly expressed in the mesenchyme surrounding the normal developing human pituitary. We analyzed Dchs2–/– mouse mutants and identified anterior pituitary hypoplasia and partially penetrant infundibular defects. Overlapping infundibular abnormalities and distinct anterior pituitary morphogenesis defects were observed in Fat4–/– and Dchs1–/– mouse mutants, but all animal models displayed normal commitment to anterior pituitary cell types. Together our data implicate FAT/DCHS protocadherins in normal hypothalamic-pituitary development and identify FAT2 and DCHS2 as candidates underlying pituitary gland developmental defects such as ectopic pituitary gland and/or pituitary stalk interruption.

Authors

Emily J. Lodge, Paraskevi Xekouki, Tatiane S. Silva, Cristiane Kochi, Carlos A. Longui, Fabio R. Faucz, Alice Santambrogio, James L. Mills, Nathan Pankratz, John Lane, Dominika Sosnowska, Tina Hodgson, Amanda L. Patist, Philippa Francis-West, Françoise Helmbacher, Constantine A. Stratakis, Cynthia L. Andoniadou

×

Figure 2

DCHS2 and FAT2 expression in the developing pituitary.

Options: View larger image (or click on image) Download as PowerPoint
DCHS2 and FAT2 expression in the developing pituitary.
(A and B) Immunof...
(A and B) Immunofluorescence staining on 17 postconception week (pcw) human fetal pituitary sections, using specific antibodies against DCHS2 (A) and FAT2 (B); n = 2. DCHS2 is expressed in mesenchymal tissues surrounding epithelial structures in the marginal zone, between the posterior and anterior pituitary and within the anterior lobe (arrows). FAT2 localizes in mesenchymal tissues within the anterior lobe and is expressed throughout the posterior lobe, and diffuse staining is observed in epithelial structures in the marginal zone. Images in middle and at right are magnified boxed regions in A and B. (C and D) Immunofluorescence staining using antibodies against FAT2 on the developing mouse pituitary at 14.5 dpc (C) and 18.5 dpc (D); n = 3. At 14.5 dpc FAT2 localizes in mesenchymal tissue, in cells of RP making contact with the mesenchyme (arrows), and in cells of the infundibulum (arrowheads) (C). At 18.5 dpc, FAT2 expression persists in the mesenchyme surrounding the gland, throughout the posterior lobe, and in vasculature throughout the anterior lobe (D). (E) In the WT adult pituitary at 10 weeks, FAT2 (shown in green) is expressed strongly by cells of the vasculature, as seen by double immunofluorescence staining with Endomucin (shown in red) marking endothelial cells; n = 3. Scale bars: 200 μm (A–C), 100 μm (E). PL, posterior lobe; AL, anterior lobe; IL, intermediate lobe, MZ, marginal zone; Inf, infundibulum; M, mesenchyme; Sph, sphenoid bone; BV, blood vessels.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts